FindTrial
Sign In

Study on Cytokines in Type 1 Leprosy Reactions

Study on levels of the Th17 and Treg pathway cytokines in Type 1 leprosy reactions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/03/041539
Enrollment
60
Registered
2022-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A308- Other forms of leprosy

Interventions

None listed

Sponsors

ABVIMS and Dr RML Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult Patients of either sex with Untreated recent Type 1 leprosy reaction, irrespective of MDT status 2.Presence of skin signs of Type 1 Leprosy reaction, with or without neuritis/ nerve function impairment

Exclusion criteria

Exclusion criteria: Those already on treatment for Type 1 reaction  Immunosuppressed patients- by way of disease or drugs Pregnancy and lactating females Presence of any other chronic illness

Design outcomes

Primary

MeasureTime frame
Levels of cytokine of Th 17 and Treg pathway in skin and blood of patients presenting with Type 1 leprosy reactionsTimepoint: Baeline and after resolution of reaction—

Secondary

MeasureTime frame
To measure levels of cytokines of Th17 and Treg pathway in non reactional leprosy patientsTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Srishti Daabas

ABVIMS and Dr RML Hospital

drananta2014@gmail.com8700552041

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026